Pliant Therapeutics, Inc. (PLRX) Dividend History

Company News

• INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

  Pliant Therapeutics has voluntarily paused enrollment and dosing in its ongoing BEACON-IPF Phase 2b trial of bexotegrast, leading to a significant drop in its stock price. Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors who suffered significant losses.

  GlobeNewswire Inc.
• Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

  Pliant Therapeutics has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis, following a recommendation by the trial's independent Data Safety Monitoring Board. The company will monitor current patients while the data is reviewed.

  GlobeNewswire Inc.
• Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

  Pliant Therapeutics presented positive data from the INTEGRIS-PSC trial, showing that their drug bexotegrast improved markers and symptoms of cholestasis and stabilized liver fibrosis in patients with primary sclerosing cholangitis.

  GlobeNewswire Inc.
• Pliant Therapeutics CBO sells shares worth over $114k - Investing.com

  Pliant Therapeutics' Chief Business Officer Hans Hull sold 9,900 shares of the company's common stock, valued at over $114,000. The sale was part of a nondiscretionary plan to satisfy withholding tax liabilities related to the vesting of performance-vested stock units.

  Investing.com
• These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings

  Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted a loss for its first quarter on Monday. Pliant Therapeutics posted a quarterly loss of 78 cents per share, versus market expectations for a loss of 77 cents per share, according to data from Benzinga Pro. Research and development expenses rose to $37.1 million from $29.3 million for the year-ago quarter, while general and administrative expenses increased to $15.2 million from $14.2 million. “In the first quarter, we made significant progress across our portfolio, highlighted by the positive safety and exploratory efficacy ...Full story available on Benzinga.com

  Benzinga